CAS: 59263-76-2; 3-(3-Ethyl-1-Methylazepan-3-yl)Phenol Hydrochloride

该化合物是一种合成化合物,主要用作止痛剂和厌毒剂,属于非类类类止痛药,具有在不与类阿片有关的上瘾性能的情况下减轻疼痛的能力,具有中枢...

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

CAS号71556-73-5 3-ethylhexahydr... | CAS号105-60-2 己内酰胺 | CAS号2556-73-2 N-甲基己内酰胺 | CAS号766-51-8 邻氯苯甲醚 | CAS号71556-70-2 六氢-1-甲基-3-(3-氧代... | CAS号71592-44-4 六氢-3-(3-羟基苯基)-1... | CAS号71592-43-3 六氢-3-(3-甲氧基苯基)-... | CAS号71556-72-4 3-ethylhexahydr... | CAS号50-00-0 甲醛 | CAS号59263-75-1 N-desmethylmept... | CAS号54340-58-8 美普他酚

合成工艺路线路线简述

    📜3-乙基六氢-3-(3-甲氧基苯基)-1-甲基-1H-氮杂卓置于盐酸体系中,化学反应 48.0H,以92%的收率获得产物盐酸美普他酚
    参考文献:Bradley; Cavalla; Edington,European Journal Of Medicinal Chemistry,1980,Vol. 15,# 4,P. 375-385
    标题:Bradley; Cavalla; Edington,European Journal Of Medicinal Chemistry,1980,Vol. 15,# 4,P. 375-385

    海关参考信息

    专利信息


    专利号:US-2012165520-A1
    优先权日:2010-12-23
    标题:Process for the synthesis of prodrugs of opioids
    发明人:MCGEE PAUL; GARNETT IAN; JUAN E; MANAGE A; CARNIAUX JEAN-FRANCOIS
    权利人:MCGEE PAUL; GARNETT IAN; JUAN E; MANAGE A; CARNIAUX JEAN-FRANCOIS
    摘要:The present invention provides a process for the synthesis of opioid prodrugs. In particular, the present invention provides a process for the synthesis of opioid prodrugs comprising: treating an opioid, in the form of a salt or a freebase, with a carbonyl synthon to form an activated intermediate and subsequently reacting the activated intermediate with an amine, in the form of a salt or a freebase.

    专利号:CN-102838541-A
    优先权日:2011-06-24
    标题 :Preparation method of intermediate â…¡ in the synthesis process of mebutamol hydrochloride

    专利号:US-2014315720-A1
    优先权日:2012-10-24
    标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
    发明人:FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
    权利人:CELANESE ACETATE LLC
    摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:General Pharmacology., 9(73), 1978 []
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知